Esperion Therapeutics Announces the Appointment of Scott Braunstein, M.D. to Board of Directors
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Esperion Therapeutics (ESPR) Adds Scott Braunstein, M.D., as Director
June 15, 2015 8:31 AM EDTEsperion Therapeutics (NASDAQ: ESPR) announced the appointment of Scott Braunstein, M.D. as a Class III Director, with a term expiring at the 2016 annual meeting of stockholders.
"I'm very pleased to welcome Dr. Braunstein to the Esperion board," said Tim Mayleben, president and chief executive officer. "With an experience base which spans the healthcare sector -- first as a practicing physician and... More
